ESR1 and breast carcinoma: Foekens et al. demonstrated a prognostic role for hsa-miR-210-3p in ER positive and negative breast cancer, while the latter was not in the scope of this study, a significant correlation between outcome and hsa-miR-210-3p expression in ER positive patients could not be validated (Figure 2G, 2H, 2I; Table 3) although expression was significantly upregulated in samples from patients with relapse in the D’Aiuto et al. data set (Figure 2H).